Phibro Animal Health Analyst Price Targets

Wall Street analyst price targets and consensus rating for Phibro Animal Health (PAHC).

Price Target Range — 9 Quarters

Analyst Consensus — 4 Analysts

1Buy

1Hold

2Sell

Consensus RatingUnderweight# Analysts4Avg. Consensus PT$34Upside to Avg. PT-8.8%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
May 14, 2026	Citigroup	Daniel Grosslight	PT Cut	Neutral	$62→$44
Apr 15, 2026	Citigroup	Daniel Grosslight	Initiate	Neutral	$62
Nov 7, 2025	JP Morgan	Ekaterina Knyazkova	PT Raise	Overweight	$45→$50
Aug 29, 2025	B of A Securities	Derik De Bruin	PT Raise	Underperform	$19→$27
Jul 7, 2025	JP Morgan	Ekaterina Knyazkova	Upgrade	Neutral→Overweight	$25→$35
Jun 25, 2025	Morgan Stanley	Erin Wright	PT Raise	Equal-Weight	$21→$26
May 8, 2025	Morgan Stanley	Erin Wright	PT Raise	Equal-Weight	$20→$21
Feb 10, 2025	Barclays	Balaji Prasad	PT Raise	Underweight	$20→$22
Dec 17, 2024	Morgan Stanley	Erin Wright	PT Raise	Equal-Weight	$20→$25
Nov 12, 2024	Barclays	Balaji Prasad	PT Raise	Underweight	$13→$20
Sep 10, 2024	JP Morgan	Ekaterina Knyazkova	Initiate	Neutral	$22
Aug 30, 2024	B of A Securities	Derik De Bruin	PT Raise	Underperform	$13→$15
May 10, 2024	Barclays	Balaji Prasad	PT Raise	Underweight	$10→$13
Nov 9, 2023	Morgan Stanley	Erin Wright	PT Cut	Equal-Weight	$17→$16

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Citigroup Maintains Neutral on Phibro Animal Health, Lowers Price Target to $44

Citigroup analyst Daniel Grosslight maintains Phibro Animal Health (NASDAQ:PAHC) with a Neutral and lowers the price target from $62 to $44.

Benzinga Newsdesk

PRO
Citigroup Initiates Coverage On Phibro Animal Health with Neutral Rating, Announces Price Target of $62

Citigroup analyst Daniel Grosslight initiates coverage on Phibro Animal Health (NASDAQ:PAHC) with a Neutral rating and announces Price Target of $62.

Benzinga Newsdesk

PRO
JP Morgan Maintains Overweight on Phibro Animal Health, Raises Price Target to $50

JP Morgan analyst Ekaterina Knyazkova maintains Phibro Animal Health (NASDAQ:PAHC) with a Overweight and raises the price target from $45 to $50.

Benzinga Newsdesk

PRO
B of A Securities Maintains Underperform on Phibro Animal Health, Raises Price Target to $27

B of A Securities analyst Derik De Bruin maintains Phibro Animal Health (NASDAQ:PAHC) with a Underperform and raises the price target from $19 to $27.

Benzinga Newsdesk

Phibro Animal Health Stock Surges 18% After-Hours On Strong Q4 Earnings Beat

Phibro shares soared nearly 18% after strong Q4 results beat estimates, driven by growth from the Zoetis MFA acquisition and solid full-year performance.

Mohd Haider

Phibro's Feed Play Pays Off: JPMorgan Upgrades On Zoetis Deal Boost

Phibro Animal Health gains JPMorgan upgrade as analyst forecasts continued growth across key livestock products and long-term fundamentals.

Vandana Singh

Phibro Animal Health Corp

Phibro Animal Health Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Citigroup Maintains Neutral on Phibro Animal Health, Lowers Price Target to $44

PRO
Citigroup Initiates Coverage On Phibro Animal Health with Neutral Rating, Announces Price Target of $62

PRO
JP Morgan Maintains Overweight on Phibro Animal Health, Raises Price Target to $50

PRO
B of A Securities Maintains Underperform on Phibro Animal Health, Raises Price Target to $27

Phibro Animal Health Stock Surges 18% After-Hours On Strong Q4 Earnings Beat

Phibro's Feed Play Pays Off: JPMorgan Upgrades On Zoetis Deal Boost

People Also Watch

People Also Watch

Phibro Animal Health Corp

Phibro Animal Health Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROCitigroup Maintains Neutral on Phibro Animal Health, Lowers Price Target to $44

PROCitigroup Initiates Coverage On Phibro Animal Health with Neutral Rating, Announces Price Target of $62

PROJP Morgan Maintains Overweight on Phibro Animal Health, Raises Price Target to $50

PROB of A Securities Maintains Underperform on Phibro Animal Health, Raises Price Target to $27

Phibro Animal Health Stock Surges 18% After-Hours On Strong Q4 Earnings Beat

Phibro's Feed Play Pays Off: JPMorgan Upgrades On Zoetis Deal Boost

People Also Watch

People Also Watch

PRO
Citigroup Maintains Neutral on Phibro Animal Health, Lowers Price Target to $44

PRO
Citigroup Initiates Coverage On Phibro Animal Health with Neutral Rating, Announces Price Target of $62

PRO
JP Morgan Maintains Overweight on Phibro Animal Health, Raises Price Target to $50

PRO
B of A Securities Maintains Underperform on Phibro Animal Health, Raises Price Target to $27